Series A funding will enable acceleration of development and commercialization of tissue-selective power tools in the EU and the US.
The company Surgify Medical has announced that it has raised seven million euros in a Series A funding round. ZEISS Ventures led this round with participation from – amongst others – Lednil, Cascara Ventures and the European Innovation Council Fund (EIC Fund). Surgify Halo™ burrs have regulatory approval under MDR and FDA 510(k), so the investment will enable the company to accelerate the commercialization of its pioneering technology across the European Union and the United States.
Founded in 2017 as a spin-out from Aalto University in Finland, Surgify Medical is specialized in the development and commercialization of surgical power tools. Its patented Surgify Halo™ technology provides unique protective capabilities against incidental injuries to easily damageable soft tissues such as central nervous system structures, blood vessels, and nerves during bone resections.
“We are thrilled to welcome ZEISS Ventures and the EIC Fund as partners in our journey,” says Visa Sippola, Co-founder and CEO of Surgify Medical. “With this funding and FDA and MDR clearance, we are well positioned to bring our unique technology to more surgeons and patients internationally.”
“We are excited to partner with Surgify in their mission to establish a new benchmark for surgical safety. Surgify’s Halo™ burrs offer exceptional control at cutting rates comparable to traditional burrs, while simultaneously safeguarding delicate soft tissues. This makes the switch to Halo™ burrs an obvious choice for surgeons,” explains Dr. Boris Hofmann, Head of ZEISS Ventures. “We are eager to support the team as they expand their solution on a global scale.”
Soft tissue damage is considered a highly relevant surgical complication in many types of head, neck and spine procedures involving bone resection and is estimated to cause more than four billion euros in complication-related costs annually in a global context.
